Advanced ovarian carcinoma; Small cell and non-small cell lung cancer; Squamous cell carcinoma of the head and neck; Advanced transitional cell carcinoma of the bladder; Significant responses have been observed when administration of SANBEPLATIN employed in the treatment of carcinoma of the cervix. SANBEPLATIN is frequently used in combination with other chemotherapeutic agent in various indications, such as with Paclitaxel in first line therapy of ovarian carcinoma and non small cell lung cancer.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
